Azilect Shortage Update

An update on Azilect shortage: As communicated recently, Teva B.V expected a mid-April date for the expected return  of Azilect 1mg supply. 

We have now received notification that Azilect supply has returned and we encourage you to contact your pharmacist to discuss further. 

Following our awareness of some members experiencing a suspected change in their Parkinson’s symptoms when switched to a generic version of medication, Parkinson’s Ireland have been in contact with the Health Products Regulatory Authority (HPRA). 

The HPRA would encourage reporting of any cases of suspected lack of efficacy via our adverse reaction reporting system.

 The most convenient option may be completion of their online form.  Also attached is a copy of the form if it is easier for you to download this and print to complete. The completed copy can be returned to the HPRA Pharmacovigilance department via post or email.

Post: Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Centre, Earlsfort Terrace, Dublin 2, D02 XP77

e-mail:  medsafety@hpra.ie

The HPRA Patient Forum recently developed a notice for patient groups with guidance on reporting any suspected safety issues, which may be helpful. Link is available here.   

The topic of generic vs brand medication for Parkinson’s patients was discussed at a recent UK Parkinsons Disease Specialist Pharmacy Network conference. Highlighting the issue to the UK pharmacy regulatory authority.  If you suspect you have also experienced adverse side effects or lack of benefit from a swap in medication please consider submitting a form (as above) to the HPRA.

Parkinson’s Ireland will continue to update members.